Purple Biotech .(US:PPBT) Globenewswire·2026-01-07 13:00Core Insights - IM1240, a tri-specific antibody from Purple Biotech's CAPTN-3 platform, has shown improved safety in a toxicology study, allowing doses up to 300-fold higher than a non-capped comparator with significantly reduced immune-related toxicity [1][2][3] - The pharmacokinetic profile of IM1240 indicates increased systemic exposure and a prolonged circulating half-life, supporting its therapeutic potential [1][3] - Purple Biotech plans to submit for regulatory approval for first-in-human clinical trials in the second half of 2026 [1] Study Results - The toxicology study demonstrated that IM1240's proprietary capping technology significantly reduced immune-related toxicity, including minimal cytokine release, compared to a non-capped comparator [2][3] - Hematologic findings in the study aligned with expected pharmacodynamic effects on immune activation, showcasing a favorable safety and tolerability profile [3] - The capping design of IM1240 allowed for a significant reduction in immune-related effects, maintaining modest cytokine release even at high doses [3] Pharmacokinetics - IM1240 exhibited a favorable pharmacokinetic profile characterized by dose-dependent increases in systemic exposure, as indicated by AUC and Cmax [3] - The findings support the dose-exposure relationship and provide proof of concept for the capping design and albumin incorporation contributing to IM1240's favorable pharmacokinetic profile [3] CAPTN-3 Platform Overview - The CAPTN-3 platform consists of capped tri-specific antibodies that target tumor-associated antigens while engaging T cells and NK cells, significantly expanding the therapeutic window compared to conventional T-cell engagers [4][5] - IM1240 targets the 5T4 antigen, while another candidate, IM1305, targets TROP2 and is currently in preclinical development [4][5] Company Background - Purple Biotech Ltd. is a clinical-stage oncology company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [5] - The company's pipeline includes additional clinical-stage assets, such as CM24 and NT219, which are in various stages of clinical trials [5]